

EFNS guidelines on diagnosis and management of neuro

European Journal of Neurology

17, 1019-1032

DOI: [10.1111/j.1468-1331.2010.03066.x](https://doi.org/10.1111/j.1468-1331.2010.03066.x)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 311-321. | 1.5 | 28 |
| 3 | Anti-AQP4-Antikörper als Biomarker zur Frühherkennung von Neuromyelitis Optica-Spektrum-Erkrankungen / AQP4-IgG antibodies as biomarkers for early diagnosis of neuromyelitis optica spectrum disorders. <i>Laboratoriums Medizin</i> , 2010, 34, 337-342. | 0.1 | 0 |
| 4 | Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses. <i>Neurochemistry International</i> , 2010, 57, 662-667. | 1.9 | 15 |
| 5 | Historia de la enfermedad de Devic. <i>Revista Colombiana De Reumatología</i> , 2011, 18, 271-284. | 0.0 | 0 |
| 6 | Longitudinal extensive transverse myelitis – it's not all neuromyelitis optica. <i>Nature Reviews Neurology</i> , 2011, 7, 688-698. | 4.9 | 141 |
| 7 | Systemic sclerosis in aquaporin-4 antibody-positive longitudinally extensive transverse myelitis. <i>Journal of the Neurological Sciences</i> , 2011, 303, 139-141. | 0.3 | 21 |
| 8 | Bilateral optic neuritis in a 26-year-old man with common variable immunodeficiency: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 319. | 0.4 | 9 |
| 9 | Azathioprine. <i>Neurology</i> , 2011, 77, 659-666. | 1.5 | 236 |
| 10 | Spinal cord tumor versus transverse myelitis. <i>Spine Journal</i> , 2011, 11, 1143-1145. | 0.6 | 16 |
| 11 | The limited demyelinating diseases: the voyage of optic neuritis and transverse myelitis to multiple sclerosis and neuromyelitis. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 451-462. | 1.4 | 3 |

12

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 21 | Current and future treatment approaches for neuromyelitis optica. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 111-121. | 1.5 | 73 |
| 22 | Impact of rituximab on relapse rate and disability in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1225-1230. | 1.4 | 141 |
| 23 | Antibodies against aquaporin-4 in neuromyelitis optica: distinction between recurrent and monophasic patients. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1527-1530. | 1.4 | 39 |
| 24 | A population-based study of neuromyelitis optica in Caucasians. <i>Neurology</i> , 2011, 76, 1589-1595. | 1.5 | 240 |
| 25 | Neuromyelitis Optica Spectrum Disease with Positive Autoimmune Indices: A Case Report and Review of the Literature. <i>Case Reports in Medicine</i> , 2011, 2011, 1-4. | 0.3 | 7 |
| 26 | Clinical approach to optic neuritis: pitfalls, red flags and differential diagnosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 123-134. | 1.5 | 69 |
| 27 | Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous System. <i>Neurology Research International</i> , 2012, 2012, 1-13. | 0.5 | 64 |
| 28 | Value of NMO-IgG determination at the time of presentation as CIS. <i>Neurology</i> , 2012, 78, 1608-1611. | 1.5 | 16 |
| 29 | Blood-Brain Barrier Disruption is More Severe in Neuromyelitis Optica than in Multiple Sclerosis and Correlates with Clinical Disability. <i>Journal of International Medical Research</i> , 2012, 40, 1483-1491. | 0.4 | 43 |
| 30 | Antibodies to MOG in NMO. <i>Neurology</i> , 2012, 79, 1198-1199. | 1.5 | 9 |
| 31 | Considerations in the design of clinical trials for relapsing multiple sclerosis. <i>Clinical Investigation</i> , 2012, 2, 1073-1083. | 0.0 | 5 |
| 32 | Plasma Exchange in Severe Attacks of Neuromyelitis Optica. <i>Multiple Sclerosis International</i> , 2012, 2012, 1-9. | 0.4 | 75 |
| 33 | Lack of Response to Pulse Cyclophosphamide in Neuromyelitis Optica. <i>Archives of Neurology</i> , 2012, 69, 938. | 4.9 | 45 |
| 34 | Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases. <i>Modern Rheumatology</i> , 2012, 22, 676-684. | 0.9 | 14 |
| 35 | Autoantibody Associated Disorders of the CNS in Children: The List Keeps Growing. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, 129-131. | 0.3 | 1 |
| 36 | Disease-specific therapy of idiopathic inflammatory demyelinating disorders. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1113-1124. | 1.4 | 2 |
| 37 | Anti-aquaporin-4 antibody-positive recurrent isolated optic neuritis and primary Sjögren's syndrome. <i>Journal of Neurology</i> , 2012, 259, 1740-1741. | 1.8 | 4 |
| 38 | Neuromyelitis optica: atypical clinic presentation. <i>Neurological Sciences</i> , 2012, 33, 1439-1442. | 0.9 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 39 | Diagnostic approach in optic neuropathy. <i>Revue Neurologique</i> , 2012, 168, 691-696. | 0.6 | 4 |
| 40 | Immunotherapies in Neurologic Disorders. <i>Medical Clinics of North America</i> , 2012, 96, 497-523. | 1.1 | 7 |
| 41 | The unfolding tale of an unusual brain stem syndrome. <i>Practical Neurology</i> , 2012, 12, 55-59. | 0.5 | 0 |
| 42 | Quantitative measurement of anti-aquaporin-4 antibodies by enzyme-linked immunosorbent assay using purified recombinant human aquaporin-4. <i>Multiple Sclerosis Journal</i> , 2012, 18, 578-586. | 1.4 | 65 |
| 43 | Acute Demyelinating Disorders: Emergencies and Management. <i>Neurologic Clinics</i> , 2012, 30, 285-307. | 0.8 | 12 |
| 44 | The Spectrum of Neuromyelitis Optica (NMO) in Childhood. <i>Journal of Child Neurology</i> , 2012, 27, 1437-1447. | 0.7 | 38 |
| 45 | Recurrent acute rhombencephalomyelitis in an adult or neuromyelitis optica? Presentation of a case. <i>Neurologia (English Edition)</i> , 2012, 27, 154-160. | 0.2 | 1 |
| 46 | A practical guide to the treatment of neuromyelitis optica. <i>Practical Neurology</i> , 2012, 12, 209-214. | 0.5 | 51 |
| 47 | Cerebrospinal Fluid BAFF and APRIL Levels in Neuromyelitis Optica and Multiple Sclerosis Patients During Relapse. <i>Journal of Clinical Immunology</i> , 2012, 32, 1007-1011. | 2.0 | 72 |
| 48 | What Started This? Debilitating Longitudinally-extensive Myelitis. <i>American Journal of Medicine</i> , 2012, 125, 1071-1073. | 0.6 | 2 |
| 49 | A 72-year-old patient with neuromyelitis optica (NMO) spectrum disorder: A case report. <i>European Geriatric Medicine</i> , 2012, 3, 240-241. | 1.2 | 0 |
| 50 | Spectrum disorder of neuromyelitis optica in a patient presenting with intractable vomiting and hiccups, transverse myelitis and acute encephalopathy. <i>Journal of Clinical Neuroscience</i> , 2012, 19, 1576-1578. | 0.8 | 12 |
| 51 | Visual evoked potentials in early diagnosis of demyelinating diseases – a case report of Devic's disease. <i>Medical Science Monitor</i> , 2012, 18, CS82-CS84. | 0.5 | 3 |
| 52 | Subacute sclerosing panencephalitis presenting as neuromyelitis optica. <i>BMJ Case Reports</i> , 2012, 2012, bcr2012006764-bcr2012006764. | 0.2 | 4 |
| 53 | Neuromyelitis optica: multiple sclerosis variant or independent disease?. <i>International Journal of Ophthalmic Practice</i> , 2012, 3, 114-121. | 0.0 | 0 |
| 54 | The differential diagnosis of longitudinally extensive transverse myelitis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 271-285. | 1.4 | 126 |
| 55 | Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. <i>Annals of Neurology</i> , 2012, 71, 314-322. | 2.8 | 232 |
| 56 | Diagnostic approach of patients with longitudinally extensive transverse myelitis. <i>Acta Neurologica Belgica</i> , 2012, 112, 39-43. | 0.5 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 57 | Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?. <i>Neuroradiology</i> , 2012, 54, 279-285. | 1.1 | 41 |
| 59 | Conventional brain MRI in neuromyelitis optica. <i>European Journal of Neurology</i> , 2012, 19, 812-819. | 1.7 | 46 |
| 60 | Immune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit. <i>Neurotherapeutics</i> , 2012, 9, 99-123. | 2.1 | 14 |
| 61 | Monoclonal antibodies in neuroinflammatory diseases. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 831-846. | 1.4 | 14 |
| 62 | Treatment of NMO relapse in the elderly: rituximab when plasma exchange fails?. <i>Acta Neurologica Belgica</i> , 2013, 113, 335-336. | 0.5 | 5 |
| 63 | Variants in the promoter region of CYP7A1 are associated with neuromyelitis optica but not with multiple sclerosis in the Han Chinese population. <i>Neuroscience Bulletin</i> , 2013, 29, 525-530. | 1.5 | 16 |
| 64 | Fulminant Demyelinating Diseases. <i>Neurohospitalist, The</i> , 2013, 3, 81-91. | 0.3 | 51 |
| 65 | Monitoring neuromyelitis optica activity. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 989-999. | 1.4 | 1 |
| 66 | Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1243-1253. | 1.9 | 10 |
| 67 | Aquaporins, anti-aquaporin-4 autoantibodies and neuromyelitis optica. <i>Clinica Chimica Acta</i> , 2013, 415, 350-360. | 0.5 | 8 |
| 68 | Neuromyelitis Optica. <i>Neurologic Clinics</i> , 2013, 31, 139-152. | 0.8 | 29 |
| 69 | Treatment of multiple sclerosis and neuromyelitis optica in children and adolescents. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, S21-S29. | 0.6 | 12 |
| 70 | Central nervous system inflammatory demyelinating disorders among Hong Kong Chinese. <i>Journal of Neuroimmunology</i> , 2013, 262, 100-105. | 1.1 | 20 |
| 71 | Seropositive Neuromyelitis Optica: A Pediatric Case Report and 6-Year Follow-Up. <i>Pediatric Neurology</i> , 2013, 49, 198-202. | 1.0 | 2 |
| 72 | Neuromielitis Óptica: actualizaci3n cl4nica y terap5utica. <i>Neurologia Argentina</i> , 2013, 5, 259-269. | 0.1 | 3 |
| 74 | A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple) Tj ETQq1 1 0.784314 rgBT /Overl | 1.4 | 7 |
| 75 | Early treatment of inflammatory demyelinating disease. <i>Nature Reviews Neurology</i> , 2013, 9, 246-247. | 4.9 | 0 |
| 76 | Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases. <i>Journal of the Neurological Sciences</i> , 2013, 328, 77-82. | 0.3 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 77 | Brain-Reactive Antibodies and Disease. Annual Review of Immunology, 2013, 31, 345-385. | 9.5 | 115 |
| 78 | Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. Journal of the Neurological Sciences, 2013, 324, 38-39. | 0.3 | 45 |
| 79 | Unusual Manifestations of Pediatric Neuromyelitis Optica. Journal of Child Neurology, 2013, 28, 658-662. | 0.7 | 8 |
| 80 | Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica. Multiple Sclerosis Journal, 2013, 19, 926-931. | 1.4 | 30 |
| 81 | Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology, 2013, 80, 1330-1337. | 1.5 | 189 |
| 82 | Meningoencephalitis as an initial manifestation of neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2013, 19, 639-643. | 1.4 | 15 |
| 83 | Optimizing the management of neuromyelitis optica and spectrum disorders in resource poor settings: Experience from the Mangalore demyelinating disease registry. Annals of Indian Academy of Neurology, 2013, 16, 572. | 0.2 | 21 |
| 84 | Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy. American Journal of Epidemiology, 2013, 178, 1139-1145. | 1.6 | 36 |
| 85 | Antibody response against gastrointestinal antigens in demyelinating diseases of the central nervous system. European Journal of Neurology, 2013, 20, 1492-1495. | 1.7 | 49 |
| 86 | Long-term MRI findings in neuromyelitis optica: seropositive versus seronegative patients. European Journal of Neurology, 2013, 20, 781-787. | 1.7 | 33 |
| 87 | Quantitative MRI Analysis of the Brain after Twenty-Two Years of Neuromyelitis Optica Indicates Damage Focal Tissue. European Neurology, 2013, 69, 221-225. | 0.6 | 3 |
| 88 | Efficacy of methylprednisolone pulse therapy for acute relapse in Japanese patients with multiple sclerosis and neuromyelitis optica: A multicenter retrospective analysis. 1. Whole group analysis. Clinical and Experimental Neuroimmunology, 2013, 4, 305-317. | 0.5 | 9 |
| 89 | Efficacy of Intravenous Cyclophosphamide Therapy for Neuromyelitis Optica Spectrum Disorder. Internal Medicine, 2013, 52, 969-972. | 0.3 | 53 |
| 91 | Patients with neuromyelitis optica have a more severe disease than patients with relapsing-remitting multiple sclerosis, including higher risk of dying of a demyelinating disease. Arquivos De Neuro-Psiquiatria, 2013, 71, 275-279. | 0.3 | 19 |
| 92 | Neuromyelitis Optica in Austria in 2011: To Bridge the Gap between Neuroepidemiological Research and Practice in a Study Population of 8.4 Million People. PLoS ONE, 2013, 8, e79649. | 1.1 | 55 |
| 93 | Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS ONE, 2013, 8, e66151. | 1.1 | 162 |
| 94 | Neuromyelitis Optica Mimicking Intramedullary Tumor. Journal of Korean Neurosurgical Society, 2013, 53, 316. | 0.5 | 6 |
| 95 | Clinical Efficacy of Plasmapheresis in Patients with Neuromyelitis Optica Spectrum Disorder and | | |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 96 | A Case of Systemic Lupus Erythematosus with Myelitis and Recurrent Neuromyelitis Optica. <i>Journal of Rheumatic Diseases</i> , 2013, 20, 64. | 0.4 | 1 |
| 97 | Clinical Correlations of Motor and Somatosensory Evoked Potentials in Neuromyelitis Optica. <i>PLoS ONE</i> , 2014, 9, e113631. | 1.1 | 7 |
| 98 | Neuromyelitis Optica Spectrum Disorder in a Chinese Woman with Ocular Myasthenia Gravis: First Reported Case in the Chinese Population. <i>Neuro-Ophthalmology</i> , 2014, 38, 140-144. | 0.4 | 2 |
| 99 | Treatment options for atypical optic neuritis. <i>Indian Journal of Ophthalmology</i> , 2014, 62, 982. | 0.5 | 12 |
| 100 | A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort. <i>Annals of Indian Academy of Neurology</i> , 2014, 17, 77. | 0.2 | 24 |
| 101 | Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system. <i>Clinical and Experimental Immunology</i> , 2014, 176, 135-148. | 1.1 | 8 |
| 102 | Allogeneic hematopoietic stem cell transplantation for neuromyelitis optica. <i>Annals of Neurology</i> , 2014, 75, 447-453. | 2.8 | 43 |
| 103 | Neuromyelitis optica spectrum disorders accompanying subarachnoid hemorrhage and reversible white matter lesions. <i>Neurology and Clinical Neuroscience</i> , 2014, 2, 10-12. | 0.2 | 3 |
| 104 | Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. <i>BMC Neurology</i> , 2014, 14, 51. | 0.8 | 40 |
| 105 | Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients. <i>BMC Neurology</i> , 2014, 14, 218. | 0.8 | 19 |
| 106 | Etiologic Spectrum and Prognosis of Longitudinally Extensive Transverse Myelopathies. <i>European Neurology</i> , 2014, 72, 86-94. | 0.6 | 22 |
| 107 | The Treatment of Neuromyelitis Optica. <i>Journal of Neuro-Ophthalmology</i> , 2014, 34, 70-82. | 0.4 | 41 |
| 108 | Clinical Manifestations and Spinal Cord Magnetic Resonance Imaging Findings in Chinese Neuromyelitis Optica Patients. <i>European Neurology</i> , 2014, 71, 35-41. | 0.6 | 10 |
| 109 | NMO spectrum disorders: how wide is the spectrum?. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1417-1419. | 1.4 | 2 |
| 110 | “Spinal amaurosis” (1841). On the early contribution of Edward Hocken to the concept of neuromyelitis optica. <i>Journal of Neurology</i> , 2014, 261, 400-404. | 1.8 | 8 |
| 111 | Overlapping demyelinating syndromes and anti-“Nâ€methylâ€aspartate receptor encephalitis. <i>Annals of Neurology</i> , 2014, 75, 411-428. | 2.8 | 405 |
| 112 | Optic neuritis. <i>Lancet Neurology</i> , The, 2014, 13, 83-99. | 4.9 | 463 |
| 113 | Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). <i>Journal of Neurology</i> , 2014, 261, 1-16. | 1.8 | 494 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 114 | Desarrollos del espectro de la neuromielitis óptica: estudio retrospectivo multicéntrico. Neurología Argentina, 2014, 6, 207-211. | 0.1 | 0 |
| 115 | Neuro-ophthalmology update. Journal of Neurology, 2014, 261, 1251-1256. | 1.8 | 4 |
| 116 | IL-17 and Glutamate Excitotoxicity in the Pathogenesis of Multiple Sclerosis. Scandinavian Journal of Immunology, 2014, 79, 181-186. | 1.3 | 77 |
| 117 | Cell-surface central nervous system autoantibodies: Clinical relevance and emerging paradigms. Annals of Neurology, 2014, 76, 168-184. | 2.8 | 159 |
| 118 | Multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 269-290. | 1.0 | 98 |
| 119 | Pearls & Oysters: A cause of intractable vomiting. Neurology, 2014, 83, e141-4. | 1.5 | 1 |
| 120 | The role of imaging in diagnosing neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2014, 3, 284-293. | 0.9 | 11 |
| 121 | A systematic analysis of the complement pathways in patients with neuromyelitis optica indicates alteration but no activation during remission. Molecular Immunology, 2014, 57, 200-209. | 1.0 | 19 |
| 122 | The neurology of Sjögren's syndrome and the rheumatology of peripheral neuropathy and myelitis. Practical Neurology, 2014, 14, 14-22. | 0.5 | 70 |
| 123 | Biomarkers for Multiple Sclerosis. Internal Medicine, 2014, 53, 361-365. | 0.3 | 36 |
| 124 | Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO "Devic's Disease): Clinic-Pathological Report and Review of the Literature. Clinical Medicine Insights: Case Reports, 2014, 7, CCRep.S15177. | 0.3 | 23 |
| 125 | Antibody biomarkers in CNS demyelinating diseases "a long and winding road. European Journal of Neurology, 2015, 22, 1162-1168. | 1.7 | 31 |
| 126 | Placebo controlled trials in neuromyelitis optica are needed and ethical. Multiple Sclerosis and Related Disorders, 2015, 4, 536-545. | 0.9 | 10 |
| 127 | The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study. PLoS ONE, 2015, 10, e0139659. | 1.1 | 15 |
| 128 | Profile of neuromyelitis optica and spectrum disorders in an Indian cohort. Journal of Neurosciences in Rural Practice, 2015, 6, 295-296. | 0.3 | 0 |
| 129 | Placebo studies should not be undertaken in NMO "Yes. Multiple Sclerosis Journal, 2015, 21, 689-691. | 1.4 | 1 |
| 130 | Longitudinally extensive transverse myelitis in systemic lupus erythematosus: Case report and review of the literature. Clinical Neurology and Neurosurgery, 2015, 129, 57-61. | 0.6 | 22 |
| 132 | Neuromyelitis optica spectrum disorders associated with other autoimmune diseases. Rheumatology International, 2015, 35, 243-253. | 1.5 | 34 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 133 | Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. <i>Multiple Sclerosis Journal</i> , 2015, 21, 189-197. | 1.4 | 56 |
| 134 | Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1178-1182. | 0.8 | 40 |
| 135 | Neuromyelitis Optica: Atypical Clinical and Neuroradiological Presentation. <i>Neuroradiology Journal</i> , 2015, 28, 41-45. | 0.6 | 5 |
| 136 | Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. <i>Journal of Neuroimmunology</i> , 2015, 282, 92-96. | 1.1 | 40 |
| 137 | Challenges and opportunities in designing clinical trials for neuromyelitis optica. <i>Neurology</i> , 2015, 84, 1805-1815. | 1.5 | 39 |
| 138 | Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics. <i>Neuroscience Bulletin</i> , 2015, 31, 745-754. | 1.5 | 6 |
| 139 | Atypical Optic Neuritis. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 76. | 2.0 | 18 |
| 140 | Embarazo y posparto en una paciente con neuromielitis Óptica de Devic y lupus eritematoso sistémico, y revisión de la literatura. <i>Neurología Argentina</i> , 2015, 7, 120-123. | 0.1 | 0 |
| 141 | Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. <i>Multiple Sclerosis Journal</i> , 2015, 21, 866-874. | 1.4 | 241 |
| 142 | Imaging of multiple sclerosis and related acquired demyelinating disorders in childhood. <i>Journal of Pediatric Neuroradiology</i> , 2015, 02, 057-072. | 0.1 | 1 |
| 143 | Intractable Hiccups and Nausea as a Principal Symptom of Neuromyelitis Optica in a Patient with a Prior History of Miller-Fisher Syndrome. <i>Journal of General and Family Medicine</i> , 2016, 17, 99-104. | 0.3 | 0 |
| 144 | Unusual Presentation of Unilateral Isolated Probable Lyme Optic Neuritis. <i>Case Reports in Neurological Medicine</i> , 2016, 2016, 1-4. | 0.3 | 8 |
| 145 | Acute Respiratory Failure due to Neuromyelitis Optica Treated Successfully with Plasmapheresis. <i>Case Reports in Pulmonology</i> , 2016, 2016, 1-3. | 0.2 | 6 |
| 146 | Neuromyelitis optica and Wernicke encephalopathy share the similar imagings, any correlations?. <i>Radiology of Infectious Diseases</i> , 2016, 3, 79-83. | 2.4 | 3 |
| 147 | Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. <i>Neurology</i> , 2016, 86, 1683-1691. | 1.5 | 149 |
| 148 | Current and future immunotherapy targets in autoimmune neurology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 133, 511-536. | 1.0 | 4 |
| 149 | Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study. <i>Journal of the Neurological Sciences</i> , 2016, 370, 224-228. | 0.3 | 56 |
| 150 | How long does it take to diagnose patients with neuromyelitis optica (NMO) using the 2006 diagnostic criteria?. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 9, 14-16. | 0.9 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 151 | The role of AQP4 in neuromyelitis optica: More answers, more questions. <i>Journal of Neuroimmunology</i> , 2016, 298, 63-70. | 1.1 | 37 |
| 152 | Early initiation of steroid pulse therapy for neuromyelitis optica in an emergency room setting. <i>Acute Medicine & Surgery</i> , 2016, 3, 171-173. | 0.5 | 0 |
| 153 | Epidemiology of Multiple Sclerosis. <i>Neurologic Clinics</i> , 2016, 34, 919-939. | 0.8 | 214 |
| 154 | Quotient of cerebrospinal fluid/serum immunoglobulin G as a predictive factor for nonresponders to intravenous methylprednisolone therapy in patients with relapsing neuromyelitis optica spectrum disorder: Implication for early initiation of plasmapheresis. <i>Clinical and Experimental Neuroimmunology</i> , 2016, 7, 272-280. | 0.5 | 2 |
| 155 | Neuromyelitis Optica (Devic's Syndrome): an Appraisal. <i>Current Rheumatology Reports</i> , 2016, 18, 54. | 2.1 | 13 |
| 156 | Placebo-controlled study in neuromyelitis optica—Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016, 22, 862-872. | 1.4 | 63 |
| 157 | Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. <i>Journal of Neurology</i> , 2016, 263, 1727-1735. | 1.8 | 45 |
| 158 | Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. <i>Annals of Neurology</i> , 2016, 79, 206-216. | 2.8 | 315 |
| 159 | Seronegative neuromyelitis optica presenting with life-threatening respiratory failure. <i>Journal of Spinal Cord Medicine</i> , 2016, 39, 734-736. | 0.7 | 4 |
| 160 | Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. <i>Journal of Neurology</i> , 2016, 263, 575-582. | 1.8 | 53 |
| 161 | Nontraumatic spinal cord injury at the neurological intensive care unit: spectrum, causes of admission and predictors of mortality. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 85-94. | 1.5 | 20 |
| 162 | Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. <i>Neurotherapeutics</i> , 2016, 13, 70-83. | 2.1 | 90 |
| 163 | Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1337-1348. | 1.4 | 32 |
| 164 | Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1192-1201. | 1.4 | 21 |
| 165 | Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 511-519. | 1.4 | 76 |
| 166 | Effects of early using azathioprine in the acute phase in neuromyelitis optica spectrum disorder. <i>International Journal of Neuroscience</i> , 2017, 127, 508-515. | 0.8 | 1 |
| 167 | Comparison of 6-mercaptopurine with 6-thioguanine for the analysis of thiopurine <i>S</i> -methyltransferase activity in human erythrocyte by LC-MS/MS. <i>Biomedical Chromatography</i> , 2017, 31, e3959. | 0.8 | 4 |
| 168 | Elevated CXCL13 and BAFF levels in neuromyelitis optica during remission. <i>Brain and Behavior</i> , 2017, 7, e00648. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 169 | Detection of Thyroid Abnormalities in Aquaporin-4 Antibodyâ€“Seropositive Optic Neuritis Patients. <i>Journal of Neuro-Ophthalmology</i> , 2017, 37, 24-29. | 0.4 | 1 |
| 170 | Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 639-647. | 0.9 | 123 |
| 171 | Neuromyelitis optica and neuromyelitis optica spectrum disorders. <i>Current Opinion in Neurology</i> , 2017, 30, 208-215. | 1.8 | 38 |
| 172 | A curious case of neuromyelitis optica spectrum disorder co-existing with idiopathic intracranial hypertension. <i>Journal of Clinical Neuroscience</i> , 2017, 41, 104-106. | 0.8 | 3 |
| 173 | The characteristics of spinal imaging in different types of demyelinating diseases. <i>Journal of the Neurological Sciences</i> , 2017, 372, 138-143. | 0.3 | 12 |
| 174 | Neurological Complications of SjÃ“grenâ€™s Syndrome: Diagnosis and Management. <i>Current Treatment Options in Rheumatology</i> , 2017, 3, 275-288. | 0.6 | 45 |
| 175 | Peduncular Hallucinosis and Autonomic Dysfunction in Anti-Aquaporin-4 Antibody Syndrome. <i>Cognitive and Behavioral Neurology</i> , 2017, 30, 116-124. | 0.5 | 7 |
| 176 | Neuromyelitis optica spectrum disorders: An experience from tertiary care hospital of Northâ€“West India. <i>Indian Journal of Medical Specialities</i> , 2017, 8, 192-196. | 0.1 | 2 |
| 177 | Immunoabsorption in neurological disorders. <i>Transfusion and Apheresis Science</i> , 2017, 56, 671-676. | 0.5 | 33 |
| 178 | Neuromyelitis Optica. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 579-591. | 0.8 | 42 |
| 179 | Patient perspectives on neuromyelitis optica spectrum disorders: Data from the PatientsLikeMe online community. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 116-122. | 0.9 | 43 |
| 180 | Hiccups as Herald: Neuromyelitis Optica Spectrum Disorder. <i>American Journal of Medicine</i> , 2017, 130, 1055-1058. | 0.6 | 2 |
| 181 | Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1377-1384. | 1.4 | 89 |
| 182 | Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. <i>Journal of the Neurological Sciences</i> , 2017, 372, 92-96. | 0.3 | 25 |
| 184 | Herpes Simplex Virus Type 2 Myelitis: Case Report and Review of the Literature. <i>Frontiers in Neurology</i> , 2017, 8, 199. | 1.1 | 26 |
| 185 | Relationship between Azathioprine metabolites and therapeutic efficacy in Chinese patients with neuromyelitis optica spectrum disorders. <i>BMC Neurology</i> , 2017, 17, 130. | 0.8 | 6 |
| 186 | Acute Clinical Worsening after Steroid Administration in Cervical Myelitis May Reveal a Subdural Arteriovenous Fistula. <i>Case Reports in Neurology</i> , 2017, 8, 234-242. | 0.3 | 10 |
| 187 | Rituximab therapy in pemphigus and other autoantibody-mediated diseases. <i>F1000Research</i> , 2017, 6, 83. | 0.8 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 188 | Severe course of neuromyelitis optica in a female patient with chronic C hepatitis. <i>Neurologia I Neurochirurgia Polska</i> , 2018, 52, 397-400. | 0.6 | 3 |
| 189 | Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. <i>Acta Neurologica Scandinavica</i> , 2018, 137, 582-588. | 1.0 | 17 |
| 190 | Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. <i>Journal of the Neurological Sciences</i> , 2018, 384, 96-103. | 0.3 | 40 |
| 191 | Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 115-121. | 0.9 | 30 |
| 192 | A Young Woman With Sudden Urinary Retention and Sensory Deficits. <i>Arthritis Care and Research</i> , 2018, 70, 635-642. | 1.5 | 3 |
| 193 | Epidemiología de la neuromielitis óptica en Costa Rica: un análisis multicéntrico. <i>Neurología Argentina</i> , 2018, 10, 185-193. | 0.1 | 2 |
| 194 | Detection of aquaporin-4 antibodies for patients with CNS inflammatory demyelinating diseases other than typical MS in Lithuania. <i>Brain and Behavior</i> , 2018, 8, e01129. | 1.0 | 5 |
| 195 | Intractable vomiting and the medulla: neuromyelitis optica spectrum disorder presenting as area postrema syndrome. <i>Postgraduate Medical Journal</i> , 2018, 94, 724-724. | 0.9 | 1 |
| 196 | Neurological Disease in Lupus: Toward a Personalized Medicine Approach. <i>Frontiers in Immunology</i> , 2018, 9, 1146. | 2.2 | 36 |
| 197 | An Overview of Autoimmune and Paraneoplastic Encephalitides. <i>Seminars in Neurology</i> , 2018, 38, 330-343. | 0.5 | 25 |
| 198 | Neuromyelitis Optica Spectrum Disorders. , 2018, , 313-335. | | 1 |
| 199 | Treating neuromyelitis optica with azathioprine: 20-year clinical practice. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1150-1161. | 1.4 | 27 |
| 200 | Clinical features and prognoses of acute transverse myelitis in patients with systemic lupus erythematosus. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 442-451. | 0.7 | 11 |
| 201 | Neuromyelitis Optica Spectrum Disorders. , 2019, , 187-195. | | 0 |
| 202 | Acute Demyelinating Disorders in the Neurocritical Care Unit. , 2019, , 414-420. | | 0 |
| 203 | Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 134. | 3.1 | 115 |
| 205 | Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. <i>Lupus</i> , 2019, 28, 1656-1662. | 0.8 | 16 |
| 206 | Letter to the Editor - Late-onset neuromyelitis optica associated with cryptogenic organizing pneumonia. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101398. | 0.9 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 207 | Herpes Simplex Virus Type 2 Radiculomyelitis Disguised as Conversion Disorder. Case Reports in Neurology, 2019, 11, 117-123. | 0.3 | 5 |
| 209 | Suspected bacterial meningoencephalomyelitis as the trigger or presentation of neuromyelitis optica spectrum disorder flare. Multiple Sclerosis and Related Disorders, 2019, 30, 38-41. | 0.9 | 9 |
| 210 | Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2019, 33, 22-32. | 0.9 | 47 |
| 211 | Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city. Multiple Sclerosis and Related Disorders, 2019, 34, 77-82. | 0.9 | 7 |
| 212 | Differential Diagnosis of Pediatric Multiple Sclerosis. Children, 2019, 6, 75. | 0.6 | 5 |
| 213 | Epidemiology of NMOSD in Sweden from 1987 to 2013. Neurology, 2019, 93, e181-e189. | 1.5 | 51 |
| 214 | Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. Journal of Neuroimmunology, 2019, 332, 126-134. | 1.1 | 14 |
| 215 | Neuromyelitis optica spectrum disorder in a tertiary hospital in the Philippines: a case series. Multiple Sclerosis and Related Disorders, 2019, 31, 124-130. | 0.9 | 6 |
| 216 | Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders. International Ophthalmology, 2019, 39, 2477-2483. | 0.6 | 24 |
| 219 | Autonomic dysfunction in people with neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2020, 26, 688-695. | 1.4 | 13 |
| 220 | Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder. Neuropathology and Applied Neurobiology, 2020, 46, 199-218. | 1.8 | 33 |
| 221 | Ocular manifestations in celiac disease: an overview. International Ophthalmology, 2020, 40, 1049-1054. | 0.6 | 17 |
| 222 | Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: A meta-analysis of real-world studies. Multiple Sclerosis and Related Disorders, 2020, 46, 102484. | 0.9 | 12 |
| 223 | Sequential intermittent therapeutic plasma exchange: A possible induction and maintenance therapy in the management of adult patients with neuromyelitis optica spectrum disorder. Therapeutic Apheresis and Dialysis, 2020, 25, 513-532. | 0.4 | 5 |
| 224 | NMOSD acute attack: Understanding, treatment and innovative treatment prospect. Journal of Neuroimmunology, 2020, 348, 577387. | 1.1 | 22 |
| 225 | Predictive Factors of Resistance to High-Dose Steroids Therapy in Acute Attacks of Neuromyelitis Optica Spectrum Disorder. Frontiers in Neurology, 2020, 11, 585471. | 1.1 | 6 |
| 226 | Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice. Multiple Sclerosis and Related Disorders, 2020, 45, 102428. | 0.9 | 42 |
| 227 | Differential Effects of MS Therapeutics on B Cellsâ€™ Implications for Their Use and Failure in AQP4-Positive NMOSD Patients. International Journal of Molecular Sciences, 2020, 21, 5021. | 1.8 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 228 | Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2608. | 1.0 | 3 |
| 229 | <p>Prognostic Factors for Visual Outcomes Following the First Episode of NMOSD-Related Optic Neuritis in Affected Eyes</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 4271-4278. | 0.9 | 9 |
| 230 | Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. <i>Frontiers in Neurology</i> , 2020, 11, 778. | 1.1 | 37 |
| 231 | Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2020, 19, 298-306. | 4.9 | 218 |
| 232 | Retrospective Observation of Low-Dose Rituximab Treatment in Chinese Patients With Neuromyelitis Optica Spectrum Disorders in a Real-World Setting. <i>Frontiers in Neurology</i> , 2020, 11, 642. | 1.1 | 13 |
| 233 | Treatment of MOG antibody associated disorders: results of an international survey. <i>Journal of Neurology</i> , 2020, 267, 3565-3577. | 1.8 | 64 |
| 234 | Astrocytes Are Required for Oligodendrocyte Survival and Maintenance of Myelin Compaction and Integrity. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 74. | 1.8 | 37 |
| 235 | Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Neurology</i> , The, 2020, 19, 391-401. | 4.9 | 183 |
| 236 | The nervous system in systemic lupus erythematosus. , 2021, , 469-478. | | 0 |
| 237 | Neuromyelitis optica spectrum disorders. <i>Journal of the Neurological Sciences</i> , 2021, 420, 117225. | 0.3 | 29 |
| 238 | Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders. <i>BioDrugs</i> , 2021, 35, 7-17. | 2.2 | 11 |
| 239 | Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. <i>Eye</i> , 2021, 35, 753-768. | 1.1 | 35 |
| 240 | Persistently Gadolinium-Enhancing Lesion Is a Predictor of Poor Prognosis in NMOSD Attack: a Clinical Trial. <i>Neurotherapeutics</i> , 2021, 18, 868-877. | 2.1 | 6 |
| 241 | Strategies to Aid Identification of Apheresis PowerFlow Ports: A Case Report. <i>Journal of Emergency Nursing</i> , 2021, 47, 21-27. | 0.5 | 4 |
| 242 | Serum Tumor Markers in Paraneoplastic Neurologic Syndromes: A Systematic Review of Guidelines. <i>Frontiers in Neurology</i> , 2020, 11, 607553. | 1.1 | 2 |
| 243 | Remedial Effect of Intravenous Cyclophosphamide in Corticosteroid-Refractory Patients in the Acute Phase of Neuromyelitis Optica Spectrum Disorder-Related Optic Neuritis. <i>Frontiers in Neurology</i> , 2020, 11, 612097. | 1.1 | 6 |
| 244 | B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders. <i>Pharmaceuticals</i> , 2021, 14, 37. | 1.7 | 6 |
| 245 | Intravenous immunoglobulin as the rescue treatment in NMOSD patients. <i>Neurological Sciences</i> , 2021, 42, 3857-3863. | 0.9 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 246 | Central nervous system demyelinating diseases in Hong Kong. <i>Neurology and Clinical Neuroscience</i> , 2021, 9, 292-300. | 0.2 | 3 |
| 247 | Meningitis as a recurrent manifestation of anti-AQP4/anti-MOG negative neuromyelitis optica spectrum disorder: a case report. <i>BMC Neurology</i> , 2021, 21, 109. | 0.8 | 3 |
| 248 | Neuromyelitis Optica Spectrum Disorder Treatmentâ€™Current and Future Prospects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2801. | 1.8 | 13 |
| 249 | New Therapeutic Landscape in Neuromyelitis Optica. <i>Current Treatment Options in Neurology</i> , 2021, 23, 13. | 0.7 | 11 |
| 250 | Longitudinally Extensive Transverse Myelitis: A Retrospective Study Differentiating Neuromyelitis Optica Spectrum Disorder From Other Etiologies. <i>Cureus</i> , 2021, 13, e13968. | 0.2 | 0 |
| 251 | Neuromyelitis Optica Spectrum Disorders (NMOSD) and Connective Tissue Disease (CTD): an Update for the Rheumatologist. <i>Current Rheumatology Reports</i> , 2021, 23, 33. | 2.1 | 16 |
| 252 | CNS autoimmunity in children: An unwanted wrinkle in a smooth narrative. <i>Medical Journal Armed Forces India</i> , 2021, 77, 138-146. | 0.3 | 0 |
| 253 | Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Immunology</i> , 2021, 12, 660382. | 2.2 | 7 |
| 254 | Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics. <i>Neurotherapeutics</i> , 2021, 18, 1623-1636. | 2.1 | 2 |
| 255 | Autoimmune Neurologic Emergencies. <i>Neurologic Clinics</i> , 2021, 39, 589-614. | 0.8 | 0 |
| 257 | UNILATERAL DIAPHRAGMATIC PALSY MIMICKING A PULMONARY SPAC OCCUPYING LESION IN A CASE OF NEUROMYELITIS OPTICA. , 2021, , 46-47. | | 0 |
| 258 | Serum neurofilament light chain and glial fibrillary acidic protein in AQP4â€™seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study. <i>Journal of Neurochemistry</i> , 2021, 159, 913-922. | 2.1 | 11 |
| 259 | Rescue immunoadsorption treatment for neuromyelitis optica spectrum disorder attacks unresponsive to intravenous methylprednisolone. <i>Journal of Neuroimmunology</i> , 2021, 356, 577604. | 1.1 | 7 |
| 260 | Establishing a second-generation artificial intelligence-based system for improving diagnosis, treatment, and monitoring of patients with rare diseases. <i>European Journal of Human Genetics</i> , 2021, 29, 1485-1490. | 1.4 | 42 |
| 261 | Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-analysis of Randomized Control Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 652759. | 1.6 | 7 |
| 262 | Magnetic resonance imaging in neuromyelitis optica spectrum disorder. <i>Clinical and Experimental Immunology</i> , 2021, 206, 251-265. | 1.1 | 14 |
| 263 | Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience. <i>Drug Discovery Today</i> , 2021, 26, 1591-1601. | 3.2 | 8 |
| 264 | Systematic review of cases of acute myelitis in individuals with COVIDâ€™19. <i>European Journal of Neurology</i> , 2021, 28, 3230-3244. | 1.7 | 31 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 265 | Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study. <i>Frontiers in Immunology</i> , 2021, 12, 720907. | 2.2 | 6 |
| 266 | COVID-19 Vaccination Attitudes With Neuromyelitis Optica Spectrum Disorders: Vaccine Hesitancy and Coping Style. <i>Frontiers in Neurology</i> , 2021, 12, 717111. | 1.1 | 9 |
| 267 | Treatment of Neuromyelitis Optica Spectrum Disorders. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8638. | 1.8 | 29 |
| 268 | Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors. <i>Neurological Sciences</i> , 2022, 43, 2651-2658. | 0.9 | 7 |
| 269 | Physical, Emotional, Medical, and Socioeconomic Status of Patients With NMOSD: A Cross-Sectional Survey of 123 Cases From a Single Center in North China. <i>Frontiers in Neurology</i> , 2021, 12, 737564. | 1.1 | 3 |
| 270 | Management of Acute Demyelinating Attacks in the Pediatric Population: A Swiss Consensus Statement. <i>Clinical and Translational Neuroscience</i> , 2021, 5, 17. | 0.4 | 1 |
| 271 | Pruritus as an initial symptom of neuromyelitis optica spectrum disorder. A peruvian case report. <i>Neuroimmunology Reports</i> , 2021, 1, 100021. | 0.2 | 0 |
| 273 | Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases. <i>Modern Rheumatology</i> , 2012, 22, 676-684. | 0.9 | 7 |
| 275 | Neuromyelitis Optica with Painful Tonic Spasms. <i>Bahrain Medical Bulletin</i> , 2015, 37, 54-56. | 0.1 | 1 |
| 276 | Systematic Review of Clinical Practice Guidelines Related to Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e106762. | 1.1 | 13 |
| 280 | New progress in the treatment of neuromyelitis optica spectrum disorder with monoclonal antibodies (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 21, 148. | 0.8 | 5 |
| 281 | Neuromyelitis optica spectrum disease characteristics in Isfahan, Iran: A cross-sectional study. <i>Journal of Research in Medical Sciences</i> , 2017, 22, 41. | 0.4 | 13 |
| 282 | Diagnostic modalities in multiple sclerosis: Perspectives in children. <i>Biomedical Journal</i> , 2014, 37, 50. | 1.4 | 11 |
| 283 | Role of low plasma volume treatment on clinical efficacy of plasmapheresis in neuromyelitis optica. <i>Asian Journal of Transfusion Science</i> , 2017, 11, 102. | 0.1 | 12 |
| 284 | Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico. , 2018, 9, 242. | | 16 |
| 285 | Role of the clinical immunology laboratory in disease monitoring. <i>World Journal of Immunology</i> , 2013, 3, 18. | 0.5 | 5 |
| 287 | Relevance of Autoantibodies for the Classification and Pathogenesis of Neurological Diseases. , 0, , | | 0 |
| 289 | Infektionen. , 2012, , 483-550. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 291 | Visual Disorders in Optic Neuromyelitis: Report of Two Cases. Journal of Clinical & Experimental Ophthalmology, 2013, , . | 0.1 | 0 |
| 293 | Comparing neuromyelitis optica and multiple sclerosis severity: is there a difference?. Arquivos De Neuro-Psiquiatria, 2013, 71, 271-272. | 0.3 | 1 |
| 294 | A Chinese Lady with Combine Neuromyelitis Optica and Sjögren's Syndrome: A Case Report. Journal of Neurophysiology and Neurological Disorders, 2013, , . | 0.0 | 0 |
| 295 | Diversity of Neuromyelitis Optica: Inner City Hospital Experience and Review of Literature. Journal of Neurology & Neurophysiology, 2014, 05, . | 0.1 | 0 |
| 296 | Efficacy of Plasma Exchange Therapy for Steroid-Unresponsive Neuromyelitis Optica. Journal of Korean Ophthalmological Society, 2014, 55, 465. | 0.0 | 1 |
| 297 | Longitudinal Ekstensif Transvers Miyelit: Olgu Sunumu. Sisli Etfal Hastanesi Tip Bulteni, 2014, , 146-9. | 0.1 | 0 |
| 298 | Neuromielitis Óptica en el embarazo: reporte de un caso. Revista Universitas Medica, 2016, 55, 456-465. | 0.0 | 0 |
| 299 | Infektionen. , 2015, , 505-575. | | 0 |
| 300 | First Experience and the Effectiveness of Immunomodulating Treatment in Inflammatory Demyelinating CNS Diseases: Analysis of Nine Patients / ImÅ«nmodulÅ«joÅ«s Terapijas EfektivitÅ«te CentrÅ«s Nervu SistÅ«mas IekaisÅ«gu SaslimÅ«janu GadÅ«jumos: DeviÅ«tu Pacientu AnalÅ«ze. Proceedings of the Latvian Academy of Sciences, 2015, 69, 269-273. | 0.0 | 0 |
| 301 | Acquired Inflammatory Diseases of the Optic Nerve: From the Neuro-Ophthalmologist's Approach. , 2016, , 361-367. | | 0 |
| 302 | Neuromyelitis Optica (Devic's Disease): A New Concept for an Old Disease. , 2016, , 351-359. | | 0 |
| 303 | Neuromyelitis Optica Spectrum Disorders: a definite case with Autoimmune Thyroiditis. International Journal of Clinical Neurosciences and Mental Health, 2016, 3, . | 0.7 | 0 |
| 305 | Ocular Manifestations of Neurologic Diseases. , 2017, , 491-516. | | 0 |
| 306 | Presentation of Neuromyelitis Optica with Recurrent Severe Myelitis and Acute Respiratory Failure in an Old Woman. Zahedan Journal of Researches in Medical Sciences, 2017, 19, . | 0.1 | 0 |
| 307 | Acute Disturbance/Loss of Vision. Ocular Trauma, 2018, , 57-94. | 0.1 | 0 |
| 308 | Inflammatory and Autoimmune Disorders of the Spinal Cord. , 2019, , 201-213. | | 0 |
| 309 | NEUROMYELITIS OPTICA-A RARE CASE. Journal of Evolution of Medical and Dental Sciences, 2019, 8, 653-655. | 0.1 | 0 |
| 310 | Comparison of Bladder Dysfunction and Urinary Symptoms Between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Caspian Journal of Neurological Sciences, 2019, 5, 105-110. | 0.1 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 311 | Neuromyelitis Optica Spectrum Disorder: A Case Report of Effective Combination Immunosuppressant, Corticosteroids, and Therapeutic Plasma Exchange. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 3433-3436. | 0.1 | 2 |
| 312 | Overview of the Current Situation and Challenges about Neuromyelitis Optica Spectrum Disorders in the Republic of Macedonia. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 40-46. | 0.1 | 0 |
| 313 | Neuromyelitis Optica Spectrum Disorders in Migrants. Sustainable Development Goals Series, 2022, , 201-212. | 0.2 | 0 |
| 314 | Neuromyelitis optica spectrum standstill in rheumatic systemic autoimmune diseases. Egyptian Rheumatology and Rehabilitation, 2020, 47, . | 0.2 | 3 |
| 315 | A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran. Iranian Journal of Neurology, 2015, 14, 204-10. | 0.5 | 17 |
| 316 | Devic's syndrome in aquaporin-4 antibody negative patient. What we need to know â€ . GMS Ophthalmology Cases, 2014, 4, Doc09. | 0.1 | 0 |
| 317 | Pathobiology, Diagnosis, and Current Biomarkers in Neuromyelitis Optica Spectrum Disorders. journal of applied laboratory medicine, The, 2022, 7, 305-310. | 0.6 | 5 |
| 318 | Management of Acute Demyelinating Attacks in the Pediatric Population: A Swiss Consensus Statement. Neuropediatrics, 2021, 52, . | 0.3 | 0 |
| 319 | Randomized Controlled Trials for Neuromyelitis Optica Spectrum Disorder. Neurologist, 2022, 27, 14-20. | 0.4 | 1 |
| 320 | Visual Evoked Potentials in Neuromyelitis Optica Spectrum Disorders. Journal of Central Nervous System Disease, 2021, 13, 117957352110573. | 0.7 | 1 |
| 321 | Review of a Case of Optic Neuromyelitis Spectrum Disease Complicated with Sjogrenâ€™s Syndrome. Advances in Clinical Medicine, 2022, 12, 91-94. | 0.0 | 0 |
| 322 | Possibilities of therapy for neuromyelitis optica spectrum disorders. Russkii Zhurnal Detskoi Nevrologii, 2022, 16, 49-58. | 0.1 | 0 |
| 323 | A prospective study on tryptophan immunoadsorption in AQP4 antibodyâ€™positive neuromyelitis optica spectrum disorders. Journal of Clinical Apheresis, 2022, , . | 0.7 | 1 |
| 324 | Neuromyelitis Optica Spectrum Disorder Associated with Cryptogenic Organizing Pneumonia in a Young Patient. European Journal of Case Reports in Internal Medicine, 2022, 9, 003105. | 0.2 | 0 |
| 325 | Relapsing neuromyelitis optica spectrum disorder. Journal of Dr NTR University of Health Sciences, 2021, 10, 269. | 0.0 | 0 |
| 327 | A Case of Neuromyelitis Optica: Puerto Rican Woman with an Increased Time Lag to Diagnosis and a High Response to Eculizumab Therapy. Case Reports in Neurological Medicine, 2022, 2022, 1-5. | 0.3 | 0 |
| 328 | Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD. Neurotherapeutics, 2022, 19, 808-822. | 2.1 | 14 |
| 329 | Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration. Multiple Sclerosis and Related Disorders, 2022, 60, 103730. | 0.9 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 330 | Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review. <i>Life</i> , 2022, 12, 19. | 1.1 | 3 |
| 331 | Internuclear Ophthalmoplegia Characterizes Multiple Sclerosis Rather Than Neuromyelitis Optica Spectrum Disease. <i>Journal of Neuro-Ophthalmology</i> , 2022, Publish Ahead of Print, . | 0.4 | 1 |
| 332 | Pain Symptoms in Optic Neuritis. <i>Frontiers in Pain Research</i> , 2022, 3, 865032. | 0.9 | 4 |
| 335 | Human Umbilical Cord Mesenchymal Stem Cells to Treat Neuromyelitis Optica Spectrum Disorder (hUCâ€“MSCâ€“NMOSD): A Study Protocol for a Prospective, Multicenter, Randomized, Placebo-Controlled Clinical Trial. <i>Frontiers in Neurology</i> , 2022, 13, 860083. | 1.1 | 4 |
| 336 | Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patientsâ€™ Perspective: An Observational Cross-Sectional Study. <i>Neurology and Therapy</i> , 2022, 11, 1101-1116. | 1.4 | 3 |
| 337 | Optic neuritis with potential for poor outcome. <i>Practical Neurology</i> , 2022, , practneurol-2021-003228. | 0.5 | 0 |
| 338 | Disease Course and Outcomes in Patients With the Limited Form of Neuromyelitis Optica Spectrum Disorders and Negative AQP4-IgG Serology at Disease Onset: A Prospective Cohort Study. <i>Journal of</i> | | |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 350 | Kaleidoscopic nervous system involvement in the setting of a chronic multisystem dysimmune disorder: report of a remarkable case. Romanian Journal of Neurology/ Revista Romana De Neurologie, 2013, 12, 70-86. | 0.1 | 2 |
| 351 | Az autoantitest-vizsgálatok jelentősége szisztémás lupus erythematosusban. Orvosi Hetilap, 2022, 163, 1695-1703. | 0.1 | 1 |
| 352 | Neuromyelitis optica: Clinical course and potential prognostic indicators. Multiple Sclerosis and Related Disorders, 2023, 69, 104414. | 0.9 | 3 |
| 353 | Plasmapheresis for Neuromyelitis Optica: A Review from the Transfusion Medicine Specialist's Perspective. European Medical Journal Neurology, 0, , 95-101. | 0.0 | 1 |
| 354 | Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2022, 14, 139-148. | 0.2 | 4 |
| 355 | A RARE CASE NEUROMYELITIS OPTICA SPECTRUM DISORDER. , 2022, , 86-87. | | 0 |
| 356 | Predictors for Acute Respiratory Failure in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorders Patients with Medullary Lesions. SSRN Electronic Journal, 0, , . | 0.4 | 0 |
| 357 | Comparison of clinico-radiological profile, optical coherence tomography parameters, and outcome in MOGAD and Neuromyelitis optica spectrum disorder subtypes: A prospective observational study. Journal of Neurosciences in Rural Practice, 0, , . | 0.3 | 1 |
| 358 | Understanding Treatment Decisions in Neuromyelitis Optica Spectrum Disorder: A Global Clinical Record Review with Patient Interviews. Neurology and Therapy, 2023, 12, 619-633. | 1.4 | 3 |
| 359 | Characterization of Disease Severity and Stability in NMOSD: A Global Clinical Record Review with Patient Interviews. Neurology and Therapy, 2023, 12, 635-650. | 1.4 | 3 |
| 361 | Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis. Journal of Neurology, 2023, 270, 2950-2963. | 1.8 | 2 |
| 362 | The neuro-ophthalmological manifestations of NMOSD and MOGAD—a comprehensive review. Eye, 2023, 37, 2391-2398. | 1.1 | 3 |